<DOC>
	<DOCNO>NCT01861834</DOCNO>
	<brief_summary>To provide child dependent total parenteral nutrition Omegaven® , fish oil-based intravenous lipid emulsion may less hepatotoxic conventional , vegetable oil-based intravenous lipid emulsion , may therefore reduce need liver transplantation .</brief_summary>
	<brief_title>Safer Parenteral Nutrition Pediatric Short Bowel Syndrome Decrease Liver Damage</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>The targeted population enrollment cohort patient TPNdependent short bowel syndrome , define pediatric patient , follow abdominal surgery , residual small bowel length le 25 % predict gestational age require postoperative TPN 42 day gastrointestinal intolerance develop TPNassociated liver disease sufficient pose significant risk progression liver failure base follow criterion : Total serum bilirubin concentration great 3 mg/dL total duration TPN great 2 month absence proven episode bacteremia within precede 3 week . PLUS EITHER : • Platelet count le 200,000/μL total duration TPN great 2 month absence proven episode bacteremia within precede 3 week . OR • Serum albumin concentration le 3.2 mg/dL total duration TPN great 2 month absence proven episode bacteremia within precede 3 week . Patients coagulopathy due parenteral nutritionassociated liver disease ( INR &gt; 1.2 ) potential candidate enrollment , patient elevate INR exceed 2 demonstrated resolution coagulopathy treatment Omegaven® . Similarly , patient hyperlipidemia potential candidate enrollment . Alternatively , patient currently receive Omegaven initiate another center intestinal failure liver disease need meet lab criterion list . The subject may continue Omegaven protocol discretion Principle Investigator . Patients history follow exclude enrollment protocol : Allergy fish egg protein . Liver disease proven suspect caused process TPNdependent short bowel syndrome , include limited hepatitis C , hepatitis B , cystic fibrosis , biliary atresia , Alagille syndrome , familial intrahepatic cholestasis , alpha1antitrypsin deficiency . Refusal third party provider reimburse hospital cost Omegaven® .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Total parenteral nutrition</keyword>
	<keyword>TPN</keyword>
	<keyword>Intestinal Failure</keyword>
	<keyword>Short Bowel Syndrome</keyword>
	<keyword>Cholestasis</keyword>
	<keyword>Intestinal failure associate liver disease</keyword>
	<keyword>Parenteral nutrition associate liver disease</keyword>
</DOC>